Financials
| H1 and Q2 2025 results | Jul. 29, 2025 |
| 1st Quarter Results | Apr. 29, 2025 |
| Annual Financial Report | Feb. 18, 2025 |
| 2024 Annual Report & 20-F Information | Feb. 18, 2025 |
| Final Results | Feb. 06, 2025 |
| 9M and Q3 2024 Results | Nov. 12, 2024 |
| Half-year Report | Jul. 25, 2024 |
Proxies
| Form of Proxy | Sep. 29, 2025 |
| Result of AGM | Apr. 11, 2025 |
| Special Business Approved at AGM | Apr. 12, 2024 |
| Proxy Form for 2024 AGM | Mar. 07, 2024 |
| Notice of AGM | Mar. 07, 2024 |
| Notice of AGM | Mar. 07, 2024 |
| Special Business Approved at AGM | Apr. 27, 2023 |
Ownership Update
| Director/PDMR Shareholding | Sep. 25, 2025 |
| Holding(s) in Company | Aug. 28, 2025 |
| Holding(s) in Company | Aug. 26, 2025 |
| Holding(s) in Company | Aug. 21, 2025 |
| Director/PDMR Shareholding | Aug. 18, 2025 |
| Holding(s) in Company | Aug. 15, 2025 |
| Holding(s) in Company | Aug. 12, 2025 |
Announcements
| Baxdrostat met primary endpoint in Bax24 Ph3 trial | Oct. 07, 2025 |
| Datroway improved OS and PFS in TROPION-Breast02 | Oct. 06, 2025 |
| Total Voting Rights | Oct. 01, 2025 |
| Enhertu improved IDFS in early BC in DB-05 | Sep. 29, 2025 |
| AZN harmonises listing structure | Sep. 29, 2025 |
| Circular and Notice of General Meeting | Sep. 29, 2025 |
| Existing Articles of Association of AstraZeneca PLC marked up to show proposed changes | Sep. 29, 2025 |
Prospectuses
| AstraZeneca prices a €1.4bn bond offering | Jul. 30, 2024 |
| AstraZeneca prices a $5bn bond offering | Feb. 22, 2024 |
| AstraZeneca prices a $2.25bn bond offering | Mar. 01, 2023 |
| AstraZeneca PLC;AstraZeneca Finance LLC - Base prospectus (debt) | Jun. 15, 2022 |
| AstraZeneca prices a EUR800m bond offering | May. 27, 2021 |
| AstraZeneca prices a $7bn bond offering | May. 26, 2021 |
| AstraZeneca PLC;AstraZeneca Finance LLC - Base prospectus (debt) | May. 24, 2021 |